We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

MAVENCLAD™ DEMONSTRATED SIGNIFICANT REDUCTIONS IN MRI ACTIVITY OVER 96 WEEKS VS. PLACEBO1

Brain Lesions 1

Number of T1 Gd+ lesions over 96 weeks (secondary endpoint)2*

Brain Lesions 2

Number of active T2-weighted lesions over 96 weeks (secondary endpoint)2*

Learn more about MAVENCLAD

 

Demonstrated reduction in ARR

Relapse-free rate
 

Demonstrated reduction in 3-month EDSS progression

 
 

See how MAVENCLAD achieved
a 57.6% relative reduction in ARR  over 96 weeks vs. placebo
(p<0.001, 0.14 vs. 0.33, respectively).

Learn more

See how MAVENCLAD allowed
79.7% of patients to remain relapse-free at 96 weeks
(vs. placebo, 79.7 vs. 60.9, respectively; p<0.001;
secondary endpoint).

Learn more

See how MAVENCLAD delivered
a 33% reduction in risk of disability
progression (EDSS) vs. placebo (p=0.02,
HR: 0.67, secondary endpoint).

Learn more

 
Footnotes and References

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; MRI=magnetic resonance imaging 

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.